Lancashire and South Cumbria
Formulary
Formulary
5 Infections
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns. |
05-03-01 Other antiretrovirals
Other drugs for the treatment of HIV infection are available on request. Contact pharmacy for advice.
Other drugs for the treatment of HIV infection are available on request. Contact pharmacy for advice.
| Abacavir with Dolutegravir and Lamivudine Triumeq® |
|
Formulary
|
Tablets abacavir (as abacavir sulfate) 600 mg, dolutegravir (as dolutegravir sodium) 50 mg, lamivudine 300 mg
|
 MHRA: Abacavir: risk of myocardial infarction—update from epidemiological studies |
|
Specialist prescribing only| Darunavir with Cobicistat Rezolsta® |
|
Formulary
|
Tablets cobicistat 150mg, darunavir (as darunavir ethanolate) 800mg
|
|
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects MHRA: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 |
|
|
| Darunavir with Cobicistat, Emtricitabine and Tenofovir alafenamide Symtuza® |
|
Formulary
|
Tablets cobicistat 150 mg, darunavir (as darunavir ethanolate) 800 mg, emtricitabine 200 mg, tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 mg
|
|
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects MHRA: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 |
|
|
| Dolutegravir and Lamivudine Dovato® |
|
Formulary
|
Tablets dolutegravir (as dolutegravir sodium) 50mg, Lamivudine 300mg
|
|
MHRA: Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects |
|
|
Specialist prescribing only| Dolutegravir and Rilpivirine Juluca® |
|
Formulary
|
Tablets 50mg/25mg
|
|
MHRA: Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects |
|
|
Links
- Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older) - Supply Disruption
Blackpool Teaching Hospitals: Antimicrobial Formulary- British Association for Sexual Health and HIV
- British HIV Association: Current Guidelines
- Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
- Clinical commissioning policy statement: Stribild for the treatment of HIV-1 infection in adults
- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- HIV Drug Interactions
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab
- LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab
- LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab
- MHRA Drug Safety Update July 2018: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA Drug Safety Update Oct 2018: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
- MHRA Drug Safety Update Oct 2018: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
- MHRA Drug Safety Update Oct 2020: Dolutegravir (Tivicay, Triumeq, Juluca): updated advice on increased risk of neural tube defects
- MHRA Drug Safety Update Oct 2020: Dolutegravir (Tivicay, Triumeq, Juluca): updated advice on increased risk of neural tube defects
- MHRA Drug Safety Update: Abacavir: risk of myocardial infarction—update from epidemiological studies
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Etravirine: reports of severe hypersensitivity reactions
- MHRA Drug Safety Update: Saquinavir: update on potential risk of arrhythmia
- MHRA DSU April 2019: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA safety information on adverse effects April 2011
- MHRA: Abacavir: risk of myocardial infarction—update from epidemiological studies
- MHRA: Abacavir: risk of myocardial infarction—update from epidemiological studies
- MHRA: Abacavir: risk of myocardial infarction—update from epidemiological studies
- MHRA: Abacavir: risk of myocardial infarction—update from epidemiological studies
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: COVID-19 antivirals: reporting to the UK COVID-19 Antivirals Pregnancy Registry
- MHRA: COVID-19 antivirals: reporting to the UK COVID-19 Antivirals Pregnancy Registry
- MHRA: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects
- MHRA: Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects
- MHRA: Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects
- MHRA: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Etravirine: reports of severe hypersensitivity reactions
- MHRA: Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir
- MHRA: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
- MHRA: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
- MHRA: Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation
- NHS England Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older)
- NICE CG165: Hepatitis B (chronic) - incorporates TA173
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE ES27: COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG191 COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
- NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B
- NICE TA757: Cabotegravir with rilpivirine for treating HIV-1
- NICE TA757: Cabotegravir with rilpivirine for treating HIV-1
- NICE TA757:Cabotegravir with rilpivirine for treating HIV-1
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA900:Tixagevimab plus cilgavimab for preventing COVID-19
- NICE TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
- Publication of an interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older).
- University Hospitals of Morecambe Bay: Antimicrobial guide secondary care
- West Lancashire Primary Care: Pan Mersey antimicrobial guide
- WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023